The Global Market for Antisense & RNAi Therapeutics is Projected to Grow at a CAGR of 8.67% During 2019-2023, Led by Alnylam Pharmaceuticals, Bausch Health, Biogen, and Sarepta Therapeutics

DUBLIN, Nov 19, 2018 /PRNewswire/ --

The "Global Antisense and RNAi Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The Global Antisense and RNAi Therapeutics Market is projected to grow at a CAGR of 8.67% during the period 2019-2023.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend affecting this market is the growing potential to address multiple therapy areas. Antisense and RNAi therapeutics can regulate the expression of genes inside the cells and they are known to have enough potential to address multiple therapy areas.

According to the report, one driver influencing this market is the high target affinity and specificity of RNAi therapeutics. The global antisense and RNAi therapeutics market is expected to witness a speedy growth owing to rising adoption of antisense and RNAi therapeutics as an effective option for the treatment of many deadly diseases such as cancers and HIV-AIDS.

Further, the report states that one challenge affecting this market is the high price of RNAi drugs. RNAi drugs provide their worth, but at the same time, their exorbitant price makes them unaffordable for a wide variety of patients, which may impede the growth of the market.

Key Vendors

• Alnylam Pharmaceuticals
• Bausch Health
• Biogen
• Sarepta Therapeutics

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: MARKET SEGMENTATION BY TYPE

• Market segmentation by type
• Comparison by type
• Antisense therapy - Market size and forecast 2018-2023
• RNAi therapy - Market size and forecast 2018-2023
• Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY APPLICATION

• Segmentation by application
• Cardiovascular diseases
• Cancer
• Metabolic disorders

PART 10: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 15: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Alnylam Pharmaceuticals
• Bausch Health
• Biogen
• Sarepta Therapeutics

For more information about this report visit https://www.researchandmarkets.com/research/369g3f/the_global_market?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/the-global-market-for-antisense--rnai-therapeutics-is-projected-to-grow-at-a-cagr-of-8-67-during-2019-2023--led-by-alnylam-pharmaceuticals-bausch-health-biogen-and-sarepta-therapeutics-300752886.html

SOURCE Research and Markets